An international policy on returning genomic research results
- PMID: 34266500
- PMCID: PMC8281644
- DOI: 10.1186/s13073-021-00928-5
An international policy on returning genomic research results
Abstract
The Global Alliance for Genomics and Health has approved a policy for the return of clinically actionable genomic research results, the first such policy approved by an international body. The policy acknowledges the potential medical benefits to millions of individuals who are participating in genomics research. It ties the pace of implementation to each country's clinical standards, including for the return of secondary findings, and urges funders to set aside resources to support responsible return.
© 2021. The Author(s).
Conflict of interest statement
ACFL owns equity in Fabric Genomics. RCG has received consulting fees from AIA, Genomic Life, Grail, OptumLabs, and Verily and is co-founder and advisor to Genome Medical. BMK declares that they have no competing interests.
References
-
- Global Alliance for Genomics and Health. Policy on Clinically Actionable Genomic Research Results. https://www.ga4gh.org/wp-content/uploads/2021-Policy-on-Clinically-Actio... (2021). Accessed June 30th.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
